2020
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
Reisenbichler ES, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison BT, Kuba MG, Ly A, Miller D, Podoll M, Roden AC, Singh K, Sanders MA, Wei S, Wen H, Pelekanou V, Yaghoobi V, Ahmed F, Pusztai L, Rimm DL. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Modern Pathology 2020, 33: 1746-1752. PMID: 32300181, PMCID: PMC8366569, DOI: 10.1038/s41379-020-0544-x.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNegative breast cancerOverall percent agreementPD-L1Intraclass correlation coefficientBreast cancerAdvanced triple-negative breast cancerPD-L1 positive casesImmune cell stainingMultiple pathologistsPD-L1 scoringMulti-institutional evaluationLung cancer studiesAtezolizumab therapySP142 assaySP263 assaysPatient selectionSP263SP142US FoodDrug AdministrationPathologist's assessmentPositive casesReal-world settingPercent agreementThe path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
Gonzalez‐Ericsson P, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Lænkholm A, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent‐Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta‐Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault‐Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, Bairi K, Harbeck N, Cimino‐Mathews A, Sotiriou C, Adams S, Liu S, Loibl S, Chen I, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon‐Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M, Group I. The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. The Journal Of Pathology 2020, 250: 667-684. PMID: 32129476, DOI: 10.1002/path.5406.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerTumor-infiltrating lymphocytesPD-L1Breast cancerPatient selectionInter-reader reproducibilityEarly-stage triple-negative breast cancerPD-1/PD-L1 inhibitorsStage triple-negative breast cancerAdvanced triple-negative breast cancerPD-1/PD-L1High tumor-infiltrating lymphocytesImmune checkpoint inhibitor therapyAddition of atezolizumabPD-L1 assessmentSuboptimal patient selectionCheckpoint inhibitor therapyOptimal patient selectionPD-L1 expressionPD-L1 inhibitorsDaily practiceStandard of careImmuno-therapeutic approachesNegative breast cancerEosin-stained slides
2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Journal For ImmunoTherapy Of Cancer 2018, 6: 75. PMID: 30012210, PMCID: PMC6048854, DOI: 10.1186/s40425-018-0382-2.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerCheckpoint inhibitorsLung cancerDurable responsesConsensus statementStage III non-small cell lung cancerAdvanced non-small cell lung cancerCancer consensus statementSequencing of therapySecond-line settingAppropriate patient selectionOnly treatment optionAdverse event managementCancer-related mortalityImmunotherapy of cancerEvidence-based recommendationsNew treatment approachesStrength of evidenceAdvanced diseasePatient selectionTargetable mutationsTreatment optionsCancer immunotherapy
2009
Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840.
Rimm D, Broadwater G, Friedman P, Berry D, Seidman A, Hudis C, Winer E, Harris L, Thor A. Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. Cancer Research 2009, 69: 6046. DOI: 10.1158/0008-5472.sabcs-6046.Peer-Reviewed Original ResearchPrediction of responseHER2 expressionCooperative group clinical trialsPositive HER2 expressionGroup clinical trialReceiver operator characteristic curveOperator characteristic curveSubset of casesArea of expressionHeterogeneity of expressionHER2 stainingTH armNeoadjuvant settingStable diseaseProgressive diseaseRECIST criteriaPartial responseClinical outcomesCAP guidelinesPatient selectionPercentage of tissueT therapyClinical trialsHER2 testsLarge cohort
2008
Molecular Classification of HPV‐Associated Head Neck Cancer
Weinberger P, Yu Z, Kountourakis P, Sasaki C, Kowalski D, Rimm D, Camp R, Amanda P. Molecular Classification of HPV‐Associated Head Neck Cancer. Otolaryngology 2008, 139: p91-p91. DOI: 10.1016/j.otohns.2008.05.497.Peer-Reviewed Original ResearchHPV DNA presenceClass II tumorsII tumorsClass IP16 expressionDNA presenceNeck squamous cell carcinomaHPV-specific therapiesHuman papillomavirus presenceSquamous cell carcinomaHead neck cancerP16 expression statusDistinct molecular phenotypesPatient selectionCell carcinomaNeck cancerExpression statusTumor progressionTumorsClass IIIMethods ParaffinClass IIMolecular classificationSpearman correlationDistinct subgroups